Y-Intercept (HK)
ARQT icon

Y-Intercept (HK)’s Arcutis Biotherapeutics ARQT Stock Holding History

Y-Intercept (HK)’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-75,572
Closed -$1.98M – 1579
2026
Q2 		$1.98M Buy
+75,572
New +$1.76M 0.04% 709
2025
Q4 		– Sell
-37,869
Closed -$714K – 1523
2025
Q3 		$714K Buy
+37,869
New +$597K 0.02% 1124
2024
Q3 		– Sell
-37,730
Closed -$351K – 1291
2024
Q2 		$351K Buy
+37,730
New +$341K 0.02% 972
2024
Q1 		– Sell
-15,804
Closed -$51K – 1351
2023
Q4 		$51K Buy
+15,804
New +$43K ﹤0.01% 1160

Other funds holding ARQT

Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Perpetual Ltd
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Jay A. Fishman Ltd
Jay A. Fishman Ltd Troy, Michigan $1.24B AUM 21.21% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return
Pavaki Capital Management
Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Y-Intercept (HK)'s ARQT Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Arcutis Biotherapeutics (ARQT) in Q3 2026, closing a stake of 75,572 shares — an estimated $1.98M sold.

Y-Intercept (HK) first reported a position in ARQT in Q4 2023 and held it in 4 quarters. The position peaked at $1.98M in Q2 2026. 83 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • Y-Intercept (HK) reported no remaining Arcutis Biotherapeutics position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 75,572 Arcutis Biotherapeutics shares in Q3 2026, an estimated $1.98M.
  • Y-Intercept (HK) first reported a position in Arcutis Biotherapeutics in Q4 2023 and held it in 4 quarters.
  • Y-Intercept (HK)'s Arcutis Biotherapeutics position peaked at $1.98M in Q2 2026.
  • 83 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.